Research conducted at The Royal Marsden NHS concluded that patients suffering from non-small cell lung cancer (NSCLC) can be monitored post-treatment with the help of artificial intelligence (AI). AI will readily predict any chance of cancer recurrence in patients who are at high-risk. This platform will render the treatment more effective in terms of outcome because practitioners will be able to treat such patients before relapse occurs. The model is based on a Machine Learning (ML) algorithm, which can efficiently detect hazardous outcomes beforehand. Experts believe that it will also lessen the need for in-office follow-up sessions.
Read More from NationalHealthExecutive
